<?xml-stylesheet type='text/xsl' href='anzctrTransform.xsl'?>
<ANZCTR_Trial requestNumber="335129">
  <stage>Registered</stage>
  <submitdate>12/02/2010</submitdate>
  <approvaldate>19/02/2010</approvaldate>
  <actrnumber>ACTRN12610000168055</actrnumber>
  <trial_identification>
    <studytitle>A study looking at the effectiveness of a oral herbal supplement for helping to manage the symptoms of enlarged prostate</studytitle>
    <scientifictitle>A double-blind, randomised, placebo-controlled study of the efficacy of an orally-dosed herbal formulation for the treatment of benign prostatic hypertrophy (BPH) symptoms.</scientifictitle>
    <utrn />
    <trialacronym />
    <secondaryid>Nil</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Benign Prostatic Hypertrophy</healthcondition>
    <conditioncode>
      <conditioncode1>Alternative and complementary medicine</conditioncode1>
      <conditioncode2>Herbal remedies</conditioncode2>
    </conditioncode>
    <conditioncode>
      <conditioncode1>Renal and Urogenital</conditioncode1>
      <conditioncode2>Other renal and urogenital disorders</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>Per Capsule
Prunus Africanum stem bark: 15,000mg
Cucubita pepo seed oil:         160mg
Epilobium parviflorum:           500mg
Seronoa repens seed:           660mg 
Lycopene:                            2.1mg

Excipients:
Lecithin
Vegetable oil
Beeswax
Soya oil

Gelatin Capsules with glycerol, Opatint Blue and Opatint White

Dosage One capsule (oral) per day before meals for 12 weeks duration.</interventions>
    <comparator>Per capsule:
Lecithin                  7mg
vegetable oil         90mg
Beeswax               30mg
Soya oil              593mg

Gelatin Capsules wiht glycerol, Opatint Blue and Opatint White

Dosage: One capsule (oral) per day before meals for 12 weeks duration.</comparator>
    <control>Placebo</control>
    <interventioncode>Treatment: Other</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>A reduction in the International Prostate Symptom Score (IPSS) to assess efficacy of preparation on symptoms of benign prostatic hypertrophy</outcome>
      <timepoint>baseline
1 month
2 month
3 month</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>Evaluate saftey and tolerability of herbal preparation assessed through patient diaries and reports of side effects and through Liver Function Tests (LFT) (pathology testing) and electrolytes (pathology testing).</outcome>
      <timepoint>baseline
1 month
2 month
3 month</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Assess effect of herbal preparation on serum prostate specific antigen (PSA) levels (pathology testing).</outcome>
      <timepoint>baseline
1 month
2 month
3 month</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Assess effect of herbal preparation in reducing the sensation of not emptying bladder completely after finished urinating assessed through scoring on IPSS questionnaire.</outcome>
      <timepoint>baseline
1 month
2 month
3 month</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Assess effect of herbal preparation in reducing freqeuncy of urination any time of the day assessed through scoring on IPSS queestionnaire.</outcome>
      <timepoint>baseline
1 month
2 month
3 month</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Assess effect of herbal preparation in reducing the frequency of stopping and starting several time during urination assessed through scoring on the IPSS questionnaire.</outcome>
      <timepoint>baseline
1 month
2 month
3 month</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Assess the effect of the herbal preparation in improving the ability to postpone urination assessed through scoring on the IPSS questionnaire.</outcome>
      <timepoint>baseline
1 month
2 month
3 month</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Assess ability of herbal preparation in strengthening urinary flow aassess through scoring on the IPSS questionnaire.</outcome>
      <timepoint>baseline
1 month
2 month
3 month</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Assess the effect of the herbal preparation in improving symptoms of pushing or straining to begin urination assess through scoring on the IPSS questionnaire.</outcome>
      <timepoint>baseline
1 month
2 month
3 month</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Assess the effect of the herbal preparation in reducing the frequency of night time urination assessed through scoring on the IPSS questionnaire.</outcome>
      <timepoint>baseline
1 month
2 month
3 month</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>1. Male aged between 40-80 years
2. Medically diagnosed with benign prostatic hypertrophy
3. Minimum score of 8 on the IPSS</inclusivecriteria>
    <inclusiveminage>40</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage>80</inclusivemaxage>
    <inclusivemaxagetype>Years</inclusivemaxagetype>
    <inclusivegender>Males</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>1. Use of a drug/natural therapy for BPH or other urological symptoms within 30 days of starting the trial.
2. Recently starting a bladder training program.
3. Urogenital surgery within the last 6 months.
4. A bladder biopsy and/or cystoscopy and biopsy within 30 days of starting the trial.
5. An indwelling catheter or practice of self-catheterisation.
6. Diagnosis of chronic persistant local pathology (i.e. interstitual cystitis, bladder stones).
7. Currently taking Warfarin or other anti-coagulant therapies.
8. Diagnosis of hypertension and recieving prescribed antihypertenive medications.
9. Diagnosis with severe renal and/or hepatic insufficiency.
10. Diagnosed with genital anatomical deformaties, uncontrolled diabetes, history of spinal cord injury and uncontrolled psychiatric disorders.</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation>Randomised controlled trial</allocation>
    <concealment>An initial preliminary screening via telephone. potential participants will be required to attend the clinic for an information session and to provide consent.
 Participants will be allocated to an intervention according to their sequence of enrolement. 
Randomisation was performed by an independent company using Random Allocation Software, version 1.0, May 2004. Randomisatrion was based on a total of 60 subjects, randomly allocated to either Active or Placebo arms of equal numbers of subjects (n=30). The randomisation code will be maintained by the independent company.</concealment>
    <sequence>Randomisation will be performed using Random Allocation Software, version 1.0 by an independent company.</sequence>
    <masking>Blinded (masking used)</masking>
    <assignment>Parallel</assignment>
    <designfeatures />
    <endpoint>Safety/efficacy</endpoint>
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 2</phase>
    <anticipatedstartdate>1/02/2010</anticipatedstartdate>
    <actualstartdate />
    <anticipatedenddate />
    <actualenddate />
    <samplesize>68</samplesize>
    <actualsamplesize />
    <recruitmentstatus>Completed</recruitmentstatus>
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate />
    <postcode>4000</postcode>
    <postcode>4010</postcode>
    <postcode>4015</postcode>
    <postcode>4020</postcode>
    <postcode>4030</postcode>
    <postcode>4040</postcode>
    <postcode>4050</postcode>
    <postcode>4060</postcode>
    <postcode>4065</postcode>
    <postcode>4070</postcode>
    <postcode>4025</postcode>
    <postcode>4035</postcode>
    <postcode>4045</postcode>
    <postcode>4055</postcode>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Commercial sector/Industry</primarysponsortype>
    <primarysponsorname>Totally Natural Products</primarysponsorname>
    <primarysponsoraddress>13-14 Durian Place
Wetherill Park B.C.
NSW 1851</primarysponsoraddress>
    <primarysponsorcountry>Australia</primarysponsorcountry>
    <fundingsource>
      <fundingtype>Commercial sector/Industry</fundingtype>
      <fundingname>Totally Natural Products</fundingname>
      <fundingaddress>13-14 Durian Place
Wetherill Park B.C.
NSW 1851</fundingaddress>
      <fundingcountry>Australia</fundingcountry>
    </fundingsource>
    <secondarysponsor>
      <sponsortype>None</sponsortype>
      <sponsorname />
      <sponsoraddress />
      <sponsorcountry />
    </secondarysponsor>
    <othercollaborator>
      <othercollaboratortype>Commercial sector/Industry</othercollaboratortype>
      <othercollaboratorname>Applied Science and Nutrition</othercollaboratorname>
      <othercollaboratoraddress>188 James street
New Farm
QLD 4005</othercollaboratoraddress>
      <othercollaboratorcountry>Australia</othercollaboratorcountry>
    </othercollaborator>
  </sponsorship>
  <ethicsAndSummary>
    <summary>The primary purpose of the study is to assess whether this herbal preparation can manage and improve the symptoms associated with BPH such as increased frequency of urination, difficulties with starting stopping urination and difficulties in postponing urination.</summary>
    <trialwebsite />
    <publication />
    <ethicsreview>Approved</ethicsreview>
    <publicnotes />
    <ethicscommitee>
      <ethicname>Endevour College of Natural Health</ethicname>
      <ethicaddress />
      <ethicapprovaldate>1/11/2009</ethicapprovaldate>
      <hrec>HREC028</hrec>
      <ethicsubmitdate>1/09/2009</ethicsubmitdate>
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>Elizabeth Steels</name>
      <address>188 James street
New Farm
QLD 4005</address>
      <phone>+61 7 3162 0909</phone>
      <fax>+61 7 3852 6183</fax>
      <email>beth@asnresearch.com.au</email>
      <country>Australia</country>
      <type>Scientific Queries</type>
    </contact>
    <contact>
      <title />
      <name>Elizabeth Steels</name>
      <address>188 James street
New Farm
QLD 4005</address>
      <phone>+61 7 3162 0909</phone>
      <fax>+61 7 3852 6183</fax>
      <email>beth@asnresearch.com.au</email>
      <country>Australia</country>
      <type>Public Queries</type>
    </contact>
    <contact>
      <title />
      <name>Samantha Coulson</name>
      <address>188 James street
New Farm
QLD 4005</address>
      <phone>+61 7 3162 0909</phone>
      <fax>+61 7 3852 6183</fax>
      <email>beth@asnresearch.com.au</email>
      <country>Australia</country>
      <type>Updating Information</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
  </contacts>
</ANZCTR_Trial>